Haleon (HLN) Aktievy

Haleon plc, tillsammans med sina dotterbolag, bedriver forskning, utveckling, tillverkning och försäljning av olika konsumenthälsovårdsprodukter i Nordamerika, Europa, Mellanöstern, Afrika, Latinamerika och Asien/Stillahavsområdet. Mer information

HLN fundamental analys
Snöflinga Score
Värdering	4/6
Framtida tillväxt	1/6
Tidigare resultat	5/6
Finansiell hälsa	2/6
Utdelningar	3/6

Belöningar

Handlar till 44.3% under vår uppskattning av dess verkliga värde

Intäkterna förväntas växa med 8.15% per år

Intäkterna ökade med 6.6% under det senaste året

Riskanalys

Har en hög skuldsättning

HLN Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW460,775 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

460,775 investors already sharing narratives

View all narratives

Haleon plc Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Haleon
Historiska aktiekurser
Aktuell aktiekurs	UK£9.87
52 veckors högsta	UK£11.28
52 veckors lägsta	UK£8.65
Beta	0.25
1 månads förändring	-1.69%
3 månaders förändring	5.90%
1 års förändring	-0.40%
3 års förändring	18.06%
5 års förändring	n/a
Förändring sedan börsintroduktionen	31.60%

Senaste nyheter och uppdateringar

Seeking Alpha • Jun 15

Haleon: Waiting For A Good Entry Point In Consumer Healthcare Leader

Summary Haleon delivered a 15.6% net profit increase in 2025, driven by cost controls and margin expansion despite modest revenue decline. HLN generated £1.5B in net free cash flow, supporting £650M in share buybacks and £612M in dividends, while reducing leverage to 2.6x EBITDA. Management guided for 3–5% organic revenue growth in 2026, with Q1 organic growth at 2.2% and expectations for acceleration through the year. Valuation at 12–13x EV/EBITDA is justified by HLN’s consumer healthcare dominance. Consensus sees EBITDA multiples declining to 10–10.5x by 2028. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 15

Haleon: Waiting For A Good Entry Point In Consumer Healthcare Leader

Seeking Alpha • Mar 05

Haleon: Growing Profits And Dividend

Summary I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by free cash flow, but the 1.6% yield is less attractive compared to peers. The balance sheet is manageable with net debt at 22% of market cap, though I question the optimality of share buybacks at current prices. The current valuation, with a P/E ratio of 26, isn't compelling for new investment, though ongoing earnings growth suggests no reason for existing shareholders to sell. Read the full article on Seeking Alpha

Seeking Alpha • Dec 10

Haleon: Guidance Implies Uncertainty Around Flu Season

Summary Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3. This reflects that there is still uncertainty of how much of a plus this year's flu season will be for respiratory products, despite the weak comp. The biggest observation we make though is that the HLN stock valuation is just not attractive enough. Read the full article on Seeking Alpha

Seeking Alpha • Oct 24

Haleon: Tailwinds Are Mostly Priced In

Summary Haleon's share price increased by 20% since July, mainly driven by strong H1 2024 results and strategic moves, among them, increasing their stake in Tianjin TSKF Pharmaceutical. The upcoming launch of Eroxon and China's stimulus pack could improve future sales, but debt maturity in 2025 may hinder deleveraging plans. Institutional investor activity shows growing optimism in Q2 2024, but recent major fund buying is absent, contributing to the mixed outlook. Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a Hold rating for Haleon. Read the full article on Seeking Alpha

Seeking Alpha • Aug 06

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Summary Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future. Read the full article on Seeking Alpha

Seeking Alpha • Nov 20

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Summary Haleon plc is a promising company in the personal care products sector, with a low beta and cheap valuation. The company operates globally and has leading brands in oral health, painkillers, and vitamins. Haleon's ownership structure is interconnected with Pfizer and GSK, but divestitures could increase competitive pressures. My valuation analysis suggests the stock is significantly undervalued, implying a 44.6% upside potential and an $11.92 price target. Read the full article on Seeking Alpha

Seeking Alpha • Sep 07

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Summary Haleon's share price has slumped, but its performance is relatively better compared to its consumer staples peers and the recent listing Kenvue. HLN has delivered solid results with organic revenue growth, increased operating profits, and raised revenue forecasts for FY2023. The company is optimizing its portfolio, divesting the Lamisil brand, reducing debt, and generating strong cash flow. Power brands are driving performance. Read the full article on Seeking Alpha

Seeking Alpha • Jun 12

Haleon: A Hidden Gem In The Consumer Health Market

Summary Haleon has a strong portfolio of leading brands and is well-positioned to benefit from ongoing market expansions. The company's latest earnings were strong, with double-digit growth in both the top and the bottom line. Despite the solid fundamentals and growth, its current valuation remains discounted compared to peers. I rate the company as a buy. Read the full article on Seeking Alpha

Seeking Alpha • Feb 25

Haleon exploring sale of ChapStick Brand - report

Haleon Plc (NYSE:HLN), the consumer health unit spun off from GSK Plc last year, is evaluating a sale of its ChapStick lip balm brand. The company is working with advisers and the business could see $600 million in a potential sale, according to a Bloomberg report from Friday, which cited people familiar. Deliberations on a possible sale are said to be at an early stage. The news comes after Bloomberg late last month reported that Haleon (HLN) was in the early stages of evaluating large potential deals to increase the size of its brand portfolio. Haleon was said to be studying possible deals in the medium-to-long-term, including potentially combining with Sanofi's (SNY) $30 billion consumer-health business. Haleon (HLN) is set to report Q4 results on Thursday. Also see SA contributor Yannick Frey's piece from last month entitled "Haleon: A Great Consumer Staples Add."

Seeking Alpha • Jan 31

Haleon said to evaluate potential deals to increase its size - report

Haleon Plc (NYSE:HLN), the consumer health business spun of from pharmaceutical giant GSK Plc (GSK), is in the early stages of evaluating large potential deal to increase the size of its brand portfolio. Haleon (HLN) is studying possible deals in medium-to-long-term, including potentially combining with Sanofi's (NASDAQ:SNY) $30 billion consumer-health business, according to traders, who cited a Bloomberg report. The maker of Advil pain reliever and Aquafresh toothpaste is expected to wait until it can show several quarters of profit grown and debt paydown before it goes forward with any big transactions, according to the report. The report comes as Johnson & Johnson (JNJ) is preparing to list its consumer health business this year, though analysts cautioned on Monday that the legal judgement against J&J in talc litigation may complicate that process. Bayer (OTCPK:BAYRY) is also seeing pressure from activists investors, including one who earlier this month pushed for the German company to separate its crop sciences business from its consumer drug business.

Seeking Alpha • Aug 31

Haleon: Undervalued With Clear Catalyst Ahead

Summary Haleon has tumbled 20% since trading began in July. The stock is undervalued relative to its peers. The announcement of a dividend should boost the stock to higher levels. Earlier this year, GSK plc (GSK) decided to focus its business on vaccines and prescription medication. As a result, the company spun-off its consumer health business. The newly created company, Haleon plc (HLN), is now the largest standalone consumer health business. It owns many household brands, including Advil, Emergen-C, Tums and Sensodyne. The company is a powerhouse in the consumer staples industry, with around $11.5 billion in annual sales. The stock began trading on July 18, 2022, and has been steadily trading lower, down 20% since trading started. This article will focus on the stock's value versus peers as well as a significant catalyst that could lead to the stock finding a floor and climbing higher. Haleon Fact Sheet Haleon is Undervalued Yahoo Finance and CNBC Anyway, you analyze Haleon, it is undervalued versus its peers in the industry. Comparing Haleon to three of the biggest companies in consumer staples - Procter & Gamble (PG), Unilever (UL, UNLYF), and Kimberly-Clark (KMB) - the company stacks up well on a number of valuation metrics. Its P/E value of 14.6 is 56% below the average P/E ratio of the 3 peers. This also puts the stock at a discount to the broader S&P 500 as well. Whenever you see a stock trading at a steep discount to its peers, investors should then look at the company's margin and growth level to see if the undervaluation is warranted. Here, you can again see Haleon stacking up very well. The company has an attractive net margin of 15.7%, which is well above Unilever and Kimberly-Clark. Perhaps, more importantly, the company expects its margins to hold up even in today's challenging market environment. Haleon saw a very strong second quarter revenue growth of 12.9% and organic revenue growth of 7.5%. The organic revenue growth came from a 4% increase in price and improved volumes of 3.5%. This combination shows consumers are willing to pay higher prices to continue to buy Haleon's product lineup in a very competitive market. For the full year FY2022, the company expects organic growth of 6-8% and 4-6% over the following 2 years. This steady growth is exactly what investors want to see and is attractive versus its peers over a 5-year period. PG Revenue (Annual YoY Growth) data by YCharts Haleon Underperformance With Haleon having attractive revenue growth, healthy margins and trading at a discount relative to its peers, why has the stock performed so poorly since its debut? Both the company and the stock are in a transition period. When Haleon was spun-off from GSK, all GSK shareholders received 1 Haleon share for every GSK share they held. 54.5% of Haleon stock was held by GSK shareholders at the time of the spin-off. These investors held GSK for exposure to pharma and not necessarily consumer healthcare. As a result, many of the current GSK shareholders likely sold during the first few weeks as it didn't meet their portfolio needs or sold to raise cash in a very uncertain market. In addition, shortly after it began trading as a standalone company, news of a growing lawsuit emerged that targeted a probable carcinogen in the popular heartburn drug, Zantac. Zantac was originally formulated and sold by GSK in the 1980s. GSK's patent expired in 1997, and since then numerous pharmaceutical companies have owned the rights to Zantac, including Pfizer (PFE), Sanofi (SNY) and Boehringer Ingelheim. With the first legal proceedings of this lawsuit starting in late August, investors began to fear an outcome similar to that faced by Bayer when they agreed to a $10.9 billion settlement related to lawsuits targeting a link between Roundup and cancer. However, the lawsuit targeting Zantac is extremely complex due to the drug being sold for nearly 4 decades by numerous different pharma companies. These lawsuits will be locked up in the courts for years to come and has a long way to go before any outcome is even clear. Haleon shares fell over 10% as news of the start of the trial emerged. Haleon issued a statement about the lawsuit where they stated Haleon is not a party to any of the Zantac claims and the company never marketed Zantac in any form in the U.S. Haleon may end up having some exposure to the lawsuit, but it will likely be limited due to the number of other companies involved, and no clear result will be known for years. As a result, the issue should remain on investors' radar, but shouldn't be front of mind or alter investment decisions. Haleon Catalyst As I said above, Haleon's stock is in a transition period and in a bit of a no-man's land. It's a newly created consumer healthcare company with plenty of comps, but the biggest difference between it and its peers is the dividend. Currently, Haleon pays no dividend. As a result, it doesn't meet many investor needs or criteria. Mutual funds, pensions, endowments and retail investors are large holders of Procter & Gamble, Unilever and Kimberly-Clark because they are steady businesses during favorable and unfavorable economic conditions that pay a steady dividend. Currently, Haleon doesn't offer this steady income that many investors rely on in their portfolios. However, the company has stated they intend to start paying a dividend at the lower end of a 30-50% payout ratio. Assuming the company starts its payout ratio at 30% and EPS of 0.42, the initial dividend will likely be around $0.12-$0.13/share. This would give the stock an initial dividend yield around 2% based on its current price around $6/share. This would also give the company plenty of room to accomplish their other objective to get their net debt/EBITDA under 3 by the end of 2024.

Seeking Alpha • Aug 19

Former GSK consumer health unit Haleon hits all-time low

Haleon (NYSE:HLN), which only began trading on the NYSE on July 19, has fallen to an all-time low. The GlaxoSmithKline (GSK) consumer healthcare spinoff opened that date at $7.25. Earlier Friday, it reached a low of $5.95. Haleon (HLN) and GSK (GSK) have both been negatively impacted recently by potential exposure to litigation related to the recalled heartburn drug Zantac (ranitidine).

Seeking Alpha • Jul 20

Haleon CEO says brand recognition, gross margins will drive growth - CNBC

On its third day as a company separate from GlaxoSmithKline (GSK), Haleon (HLN) CEO Brian McNamara said that the customer recognition of its many brands combined with hits high gross margin rate will power growth in the future, he said. In an interview on CNBC's "Squawk Box" Wednesday morning, McNamara said that the former GSK (GSK) consumer healthcare unit had a gross margin of 63% and an operating margin of 22.8% in 2021. "With that gross margin and strength in brands, [it] really gives us the ability to invest in innovation and advertising and promotion to really drive the fundamental growth of the business," he added. Despite a plethora of store and generic-branded consumer healthcare products, McNamara noted that "brands really matter in the health space." Haleon (HLN) management has previously guided to 4%-6% net sales growth annually. Haleon (HLN) began trading on the London Stock Exchange on Monday. Since then, shares are down ~8%. The company made its trading debut on the NYSE today. In late morning trading, shares are up 0.4%.

Aktieägarnas avkastning

	HLN	US Pharmaceuticals	US Marknad
7D	0.7%	6.0%	-0.8%
1Y	-0.4%	59.4%	20.5%

Avkastning vs industri: HLN presterade sämre än US Pharmaceuticals branschen som gav 59.4 % under det senaste året.

Avkastning vs Marknaden: HLN presterade sämre än US marknaden som gav 20.5 % under det senaste året.

Prisvolatilitet

Is HLN's price volatile compared to industry and market?
HLN volatility
HLN Average Weekly Movement	3.5%
Pharmaceuticals Industry Average Movement	9.2%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

Stabil aktiekurs: HLN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: HLN s veckovolatilitet ( 3% ) har varit stabil under det senaste året.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
1715	24,535	Brian McNamara	www.haleon.com

Haleon plc bedriver, tillsammans med sina dotterbolag, forskning, utveckling, tillverkning och försäljning av olika hälsovårdsprodukter för konsumenter i Nordamerika, Europa, Mellanöstern, Afrika, Latinamerika och Asien-Stillahavsområdet. Företaget erbjuder munvårdsprodukter, såsom tandkrämer, munskölj och produkter för tandprotesvård under varumärkena Sensodyne, Polident, Parodontax och Biotene, samt vitaminer, mineraler och kosttillskott under varumärkena Centrum, Emergen-C och Caltrate. Företaget tillhandahåller även olika receptfria produkter, däribland näsdroppar samt produkter mot förkylning, influensa och allergi under varumärkena Theraflu och Flonase för andningsbesvär; smärtlindrande produkter under varumärkena Voltaren, Panadol och Advil; samt antacida och antihistaminer under varumärkena TUMS, ENO, och Fenistil för matsmältningshälsa och andra besvär.

Haleon plc Sammanfattning av grunderna

Hur förhåller sig Haleon:s resultat och omsättning till dess börsvärde?
HLN grundläggande statistik
Börsvärde	US$42.90b
Vinst(TTM)	US$2.21b
Intäkter(TTM)	US$15.18b

19.4x

P/E-förhållande

2.8x

P/S-förhållande

Är HLN övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
HLN resultaträkning (TTM)
Intäkter	UK£11.15b
Kostnad för intäkter	UK£3.84b
Bruttovinst	UK£7.31b
Övriga kostnader	UK£5.69b
Intäkter	UK£1.62b

Senast redovisade vinst

Jun 30, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)	0.18
Bruttomarginal	65.57%
Nettovinstmarginal	14.55%
Skuld/egenkapitalförhållande	49.2%

Hur har HLN utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Utdelningar

2.0%

Aktuell utdelningsavkastning

40%

Utbetalningskvot

Ger HLN en tillförlitlig utdelning?

Se HLN utdelningshistorik och jämförelsetal

När behöver man köpa HLN för att få en kommande utdelning?
Haleon datum för utdelning
Ex utdelningsdag	Aug 14 2026
Utbetalningsdag för utdelning	Sep 17 2026
Dagar till Ex-utdelning	7 days
Dagar till utdelningsdag	27 days

Ger HLN en tillförlitlig utdelning?

Se HLN utdelningshistorik och jämförelsetal

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/08/19 15:27
Aktiekurs vid dagens slut	2026/08/19 00:00
Intäkter	2026/06/30
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Haleon plc bevakas av 26 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Iain Simpson	Barclays
Warren Ackerman	Barclays
Bethan Davies	Berenberg

Haleon (HLN) Aktievy

Belöningar

Riskanalys

Join community and earn perks

Haleon plc Konkurrenter

Teva Pharmaceutical Industries

Royalty Pharma

Zoetis

Jazz Pharmaceuticals

Prishistorik och prestanda

Senaste nyheter och uppdateringar

Emergen-C Partners with Carl Radke’S Soft Bar to Launch Limited-Time Mocktail Experience Showcasing Multi-Benefit Support

Haleon plc Declares Interim Dividend for the First Half of 2026, Payable on 17 September 2026

Haleon: Waiting For A Good Entry Point In Consumer Healthcare Leader

Haleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct

Centrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits

Haleon Announces the Appointment of Richard Mansoas as Us Chief Marketing Officer, Effective April 27, 2026

Recent updates

Emergen-C Partners with Carl Radke’S Soft Bar to Launch Limited-Time Mocktail Experience Showcasing Multi-Benefit Support

Haleon plc Declares Interim Dividend for the First Half of 2026, Payable on 17 September 2026

Haleon: Waiting For A Good Entry Point In Consumer Healthcare Leader

Haleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct

Centrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits

Haleon Announces the Appointment of Richard Mansoas as Us Chief Marketing Officer, Effective April 27, 2026

Haleon plc, Annual General Meeting, Apr 29, 2026

Haleon plc (LSE:HLN) announces an Equity Buyback for £500 million worth of its shares.

Parodontax, the Gum Expert Brand from Haleon launches New Gum Strengthen and Protect Toothpaste and Mouthwash

Haleon plc to Report First Half, 2026 Results on Jul 30, 2026

Haleon plc Proposes Final Ordinary Dividend for Fiscal Year 2025, Payable on 14 May 2026

Sensodyne Launches Sensodyne Clinical Repair

Haleon Announces Executive Changes

Haleon plc Announces Evolution of Its Operating Model to Drive Growth and Agility

Haleon plc Announces Board and Committee Changes, with Effect from 1 January 2026

Haleon plc Announces Board Changes

Haleon plc Reiterates Earnings Guidance for the Fiscal Year 2025

Haleon plc to Report Fiscal Year 2025 Results on Feb 25, 2026

Haleon plc Appoints Bláthnaid Bergin to the Audit & Risk Committee and Matt Shattock to the Environmental & Social Sustainability Committee with Effect from 30 July 2025

Haleon plc (LSE:HLN) completed the acquisition of 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329).

Haleon plc Announces Executive Changes

Sensodyne Launches New Premium Clinical White Toothpaste to Brighten Canadians' Smile Day

Haleon plc Maintains Earnings Guidance for Year 2025 and 2026

Haleon plc (LSE:HLN) agreed to acquire 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) for CNY 1.6 billion .

Haleon plc, Annual General Meeting, May 28, 2025

Haleon: Growing Profits And Dividend

Haleon plc Proposes Final Dividend for Fiscal Year 2024, Payable on 5 June 2025

Haleon plc to Report First Half, 2025 Results on Jul 31, 2025

Bryan Supran (Non-Executive Director and Representative of Pfizer Inc.) Steps Down from the Board of Haleon plc

Pfizer Intends to Sell Approximately 700 Million Ordinary Shares in Haleon

Haleon: Guidance Implies Uncertainty Around Flu Season

Haleon plc Announces Board Changes

Haleon: Tailwinds Are Mostly Priced In

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 455,701,825 shares, representing 4.99% of its issued share capital., under the authorization approved on May 8, 2024.

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN).

Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Haleon plc Announces Directorate Change

Haleon plc Announces Management Changes

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Haleon plc, Annual General Meeting, May 08, 2024

Haleon plc to Report First Half, 2024 Results on Aug 01, 2024

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon: A Hidden Gem In The Consumer Health Market

Haleon exploring sale of ChapStick Brand - report

Haleon plc Announces Board Changes

Haleon said to evaluate potential deals to increase its size - report

Haleon: Undervalued With Clear Catalyst Ahead

Former GSK consumer health unit Haleon hits all-time low

Haleon CEO says brand recognition, gross margins will drive growth - CNBC